VNDA - Vanda Pharmaceuticals Receives Another Takeover Proposal Considers $466M Deal | Benzinga
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) received an acquisition offer from Cycle Pharmaceuticals Ltd worth $8 per share, representing a total cash consideration of $466 million.
Cycle Pharmaceuticals, founded in 2012, focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, Cycle focuses on multiple sclerosis. In May, Cycle ...